EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
Skip to content
English
Armenian
Croatian
Czech
Danish
Dutch
English
Finnish
French
German
Greek
Hebrew
Hungarian
Icelandic
Italian
Latvian
Lithuanian
Macedonian
Norwegian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Turkish
Search:
About us
Contact us
English
Armenian
Croatian
Czech
Danish
Dutch
English
Finnish
French
German
Greek
Hebrew
Hungarian
Icelandic
Italian
Latvian
Lithuanian
Macedonian
Norwegian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Turkish
Superior MPE
Myeloma Patients Europe
Myeloma and AL Amyloidosis
About Multiple Myeloma
About AL amyloidosis
What we do
Member and patient community programmes
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
COVID-19
Research
Patient Evidence
Horizon Europe
IMI
Access
Access to myeloma treatment
CEE workgroup on Access
Myeloma Trial Navigator
Educational resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Conference reports
Patient guides
European Myeloma Day
News
Privacy Policy
Cookies Policy
Facebook page opens in new window
Twitter page opens in new window
YouTube page opens in new window
Linkedin page opens in new window
EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
About MPE
Our members
Our board and staff
Medical Advisory Commitee
Our funding
Get involved in MPE activities
Become a MPE member
Contact us
Myeloma and AL Amyloidosis
About myeloma
What is myeloma?
What causes myeloma?
Coping with a myeloma diagnosis
Early diagnosis and smoldering myeloma
Diagnostic tests
Treatment of myeloma
Myeloma symptoms and treatment side-effects
Caring for yourself
Dealing with the psycho-social aspects of the disease
Managing myeloma and work, finance and advance decisions
Myeloma landscape and future directions
Clinical trials
Finding out about myeloma clinical trials
About AL amyloidosis
What are the main AL amyloidosis treatments?
How is AL amyloidosis diagnosed?
What is the relation between AL amyloidosis and myeloma?
What we do
Member and patient community programmes
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
COVID-19
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
Research
Patient Evidence
Horizon Europe
MMPredict
CARAMBA
IMI
Harmony
Sisaqol
Access
Access to myeloma treatment
CEE workgroup on Access
Myeloma and AL Amyloidosis Trial Navigator
Educational resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Conference reports
Patient guides
News
European Myeloma Day
Myeloma infographics
AL amyloidosis infographics
Videos
RIIKA LEMPIAINEN
You are here:
Home
RIIKA LEMPIAINEN
RIIKA LEMPIAINEN
Go to Top
I am a
*
Patient
Patient advocate
Caregiver
Doctor
Comments
This field is for validation purposes and should be left unchanged.
×
English
Armenian
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hungarian
Icelandic
Italian
Latvian
Lithuanian
Macedonian
Norwegian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Turkish
